Teva Pharmaceutical beats Q3 profit forecasts, raises 2026 revenue guidance
Israeli drugmaker Teva Pharmaceutical Industries reported third-quarter profit that exceeded analyst expectations, driven by strong sales of three branded medicines that offset declines in generic drugs. The company raised its full-year 2026 revenue estimates following the results.
